Phase 2 data for Cargo Therapeutics' CD22-targeting cell therapy show low durability and cases of a severe immune response, some that were classified as grade 4 or 5 serious adverse events. Cargo is discontinuing the study and shifting focus to a different cell therapy on track to begin Phase 1 testing in mid-2025.
Managing large volumes of data, often across various systems, is a significant challenge for growing healthcare organizations. This ebook will help you navigate what truly matters and find improvements in patient access and operational efficiency. Download it today!
Hone Health's Series A round included participation from Tribe Capital, PIF, Republic Capital, Vibe VC, Humbition, Hanwha, Gaingels, Looking Glass Capital, FJ Labs and Agent Capital. In total, the company has raised $39 million.
As the pool of approved therapies continues to (hopefully) expand, the clinical and diagnostic testing communities need to do a better job at ensuring the right patients move through this journey more quickly – and accurately – to improve their health and prognosis.
By insisting on coding-aware AI solutions, health systems can ensure that these technologies fulfill their transformative promise, reducing clinician burnout and administrative burden, improving patient care and communication, and accurately capturing what occurred during an encounter.
The shifting AI landscape. Learn about the emerging technologies from AI tech developers across the healthcare landscape from health tech startups to healthcare organizations, biopharma companies, and a medtech giant.
No comments:
Post a Comment